Novoray Corporation (688300.SS) Bundle
Curious whether Novoray Corporation (688300.SS) is a buy, hold or watch? Start with the numbers: Q3 2025 revenue jumped to 304.58 million CNY (+21.66% q/q) and trailing twelve-month sales sit at 1.09 billion CNY (+21.91% YoY), while full-year 2024 revenue reached 960.36 million CNY (up 34.94% YoY); profitability shows a 2024 net profit attributable to the parent of 251 million CNY (+44.47% YoY) with a net margin of 26.18%, ROE of 18.64% and TTM net income of 286.52 million CNY (EPS 1.17 CNY); the balance sheet reports total debt of 194.22 million CNY (debt/equity 0.12), a strong current ratio of 3.07 and cash of 350.88 million CNY giving a net cash position of 156.66 million CNY; cash flow and solvency metrics include operating cash flow of 260.68 million CNY, capex 96.21 million CNY and free cash flow of 164.47 million CNY, with an Altman Z‑Score of 13.67 indicating low bankruptcy risk; market valuation shows a market cap around 14.14 billion CNY (stock price 58.04 CNY on 2025-12-15), trailing P/E 47.99, forward P/E 41.35, P/S 12.97, P/B 8.35 and EV/EBITDA 38.65 - all set against identifiable risks (raw material/energy cost swings, domestic competition, regulatory shifts and demand timing) and tangible growth levers (5G/5.5G high‑frequency materials, advanced packaging demand, R&D in functional powders, thermal interface materials and localized alumina production) that investors will want to weigh closely as you read on
Novoray Corporation (688300.SS) - Revenue Analysis
Novoray Corporation reported sustained top-line growth through 2024-2025, with notable quarterly and annual acceleration. Key headline figures:- Q3 2025 revenue: 304.58 million CNY (up 21.66% QoQ).
- TTM revenue: 1.09 billion CNY (up 21.91% YoY).
- 2024 annual revenue: 960.36 million CNY (up 34.94% vs. 2023).
- Revenue per employee: 1.60 million CNY (683 employees).
- Market capitalization: 14.14 billion CNY; share price: 58.04 CNY (as of 2025-12-15).
- Price-to-sales (P/S) ratio: 12.97.
| Metric | Value | Period/Note |
|---|---|---|
| Q3 Revenue | 304.58 million CNY | Q3 2025, +21.66% QoQ |
| Trailing Twelve Months (TTM) Revenue | 1.09 billion CNY | YoY +21.91% |
| Annual Revenue | 960.36 million CNY | 2024, +34.94% YoY |
| Employees | 683 | Revenue/employee: 1.60 million CNY |
| Market Cap | 14.14 billion CNY | As of 2025-12-15 |
| Share Price | 58.04 CNY | As of 2025-12-15 |
| P/S Ratio | 12.97 | Market valuation relative to sales |
- Growth dynamics: Q3 2025 QoQ growth (21.66%) and TTM YoY expansion (21.91%) indicate accelerating demand and improving revenue run-rate versus prior-year levels.
- Efficiency: Revenue per employee at 1.60 million CNY suggests a relatively high per-capita productivity for the company's sector.
- Valuation context: P/S of 12.97 and a 14.14 billion CNY market cap imply market expectations of continued high growth or margin expansion.
Novoray Corporation (688300.SS) - Profitability Metrics
Novoray Corporation (688300.SS) demonstrated marked improvement in profitability in 2024, with across-the-board gains in margins, EPS, and returns that reflect stronger pricing power and operational leverage.- Net profit attributable to the parent (2024): 251 million CNY, up 44.47% year-over-year.
- Net profit margin (2024): 26.18%, +1.73 percentage points YoY.
- Gross profit margin (2024): 40.38%, +1.12 percentage points YoY.
- Operating margin (2024): 27.02%, indicating efficient core operations.
- Return on equity (ROE, 2024): 18.64%, signaling effective use of shareholders' equity.
- Earnings per share (EPS, 2024): 1.17 CNY; TTM net income: 286.52 million CNY.
| Metric | 2024 | YoY Change | Notes |
|---|---|---|---|
| Net profit attributable to parent | 251 million CNY | +44.47% | Substantial increase driven by margin expansion and higher revenue mix |
| Net profit margin | 26.18% | +1.73 pp | Improved cost control and favorable product mix |
| Gross profit margin | 40.38% | +1.12 pp | Higher selling prices and/or reduced COGS intensity |
| Operating margin | 27.02% | - | Shows operational efficiency before non-operating items |
| Return on equity (ROE) | 18.64% | - | Strong shareholder returns relative to equity base |
| Earnings per share (EPS) | 1.17 CNY | - | Reflects net profit allocation to common shares |
| TTM Net Income | 286.52 million CNY | - | Trailing twelve months aggregation |
Novoray Corporation (688300.SS) - Debt vs. Equity Structure
Novoray Corporation (688300.SS) presents a conservatively financed balance sheet as of March 31, 2025, characterized by low leverage, significant liquidity and a solid equity base. The company's modest total debt and substantial equity provide flexibility for reinvestment, R&D and operational scaling while keeping interest burden negligible relative to operating earnings.- Total debt: 194.22 million CNY
- Total equity: 1.63 billion CNY
- Debt-to-equity ratio: 0.12
- Net cash position: 156.66 million CNY
- Book value per share: 6.76 CNY
| Metric | Value |
|---|---|
| Total debt | 194.22 million CNY |
| Total equity | 1.63 billion CNY |
| Debt-to-equity ratio | 0.12 |
| Current ratio | 3.07 |
| Quick ratio | 1.75 |
| Interest coverage ratio | 182.32 |
| Enterprise value (EV) | 13.49 billion CNY |
| EV / EBITDA | 38.65 |
| Net cash | 156.66 million CNY |
| Book value per share | 6.76 CNY |
- Current ratio 3.07 and quick ratio 1.75 indicate ample ability to cover near-term liabilities without relying on long-term financing.
- Interest coverage of 182.32 demonstrates earnings massively exceed interest obligations, effectively minimizing refinancing risk.
- Debt-to-equity of 0.12 and net cash of 156.66 million CNY point to a low-leverage profile that supports stability and strategic optionality.
- Book value per share (6.76 CNY) provides a tangible equity floor for shareholders given the balance sheet composition.
- Enterprise value of 13.49 billion CNY versus an EV/EBITDA of 38.65 suggests market-priced expectations of high future earnings growth; investors should reconcile this multiple with operational growth prospects and margin sustainability.
Novoray Corporation (688300.SS) - Liquidity and Solvency
- Operating cash flow: 260.68 million CNY
- Capital expenditures: 96.21 million CNY
- Free cash flow: 164.47 million CNY
- Cash and cash equivalents: 350.88 million CNY
- Working capital: 931.14 million CNY
- Total assets: 1,630.00 million CNY
- Total liabilities: 194.22 million CNY
- Shareholders' equity (assets - liabilities): 1,435.78 million CNY
| Metric | Value | Interpretation |
|---|---|---|
| Operating Cash Flow (OCF) | 260.68 million CNY | Solid cash generation from operations |
| Capital Expenditures (CapEx) | 96.21 million CNY | Reinvestment level supporting growth/maintenance |
| Free Cash Flow (FCF) | 164.47 million CNY | Positive cushion for dividends, debt repayment, buybacks |
| Cash & Cash Equivalents | 350.88 million CNY | Immediate liquidity for operations |
| Working Capital | 931.14 million CNY | Adequate short-term buffer vs. current obligations |
| Total Assets | 1,630.00 million CNY | Scale of the balance sheet |
| Total Liabilities | 194.22 million CNY | Relatively low absolute leverage |
| Equity | 1,435.78 million CNY | Strong equity base |
| Debt-to-Asset Ratio | 11.91% | Low leverage (194.22/1,630) |
| Altman Z-Score | 13.67 | Very low bankruptcy risk |
| Piotroski F-Score | 4 | Moderate financial strength; room for improvement |
- High Altman Z-Score (13.67) signals strong solvency and minimal bankruptcy risk.
- Free cash flow of 164.47 million CNY and cash reserves of 350.88 million CNY underpin operational flexibility.
- Working capital of 931.14 million CNY indicates comfortable short-term coverage; debt-to-asset ≈ 11.9% shows conservative leverage.
- Piotroski F-Score at 4 points to mixed operational/accounting signals-investors should monitor earnings quality and profitability trends.
Novoray Corporation (688300.SS) Valuation Analysis
Novoray Corporation (688300.SS) is priced at a premium on several traditional valuation metrics, reflecting investor expectations for continued growth but also exposing the stock to valuation risk if earnings do not meet those expectations.
- Trailing P/E: 47.99 - investors currently pay ~48x last twelve months' earnings.
- Forward P/E: 41.35 - the market is pricing in earnings improvement, but still at a high multiple.
- Price-to-Book (P/B): 8.35 - equity is valued significantly above book value, implying strong intangibles or growth premium.
- EV/Sales: 12.37 - enterprise value relative to revenue indicates a high revenue multiple.
- EV/EBIT: 45.78 - high operating earnings multiple, consistent with elevated expectations for profitability growth.
- PEG ratio: N/A - insufficient or unreliable consensus growth inputs to calculate a meaningful PEG.
- Dividend yield: 0.68% with payout ratio: 32.55% - modest yield with a conservative payout relative to earnings.
- Market capitalization: 13.65 billion CNY; Enterprise value: 13.49 billion CNY - EV roughly in line with market cap, suggesting modest net debt/lease adjustments.
| Metric | Value | Implication |
|---|---|---|
| Trailing P/E | 47.99 | High current earnings multiple |
| Forward P/E | 41.35 | Market expects EPS growth |
| P/B | 8.35 | Significant premium to book value |
| EV/Sales | 12.37 | High revenue valuation |
| EV/EBIT | 45.78 | Large multiple on operating profit |
| PEG | N/A | No reliable growth-adjusted P/E available |
| Dividend yield | 0.68% | Low income return |
| Payout ratio | 32.55% | Conservative dividend relative to earnings |
| Market cap | 13.65 billion CNY | Equity market value |
| Enterprise value | 13.49 billion CNY | Firm value including debt/leasing adjustments |
Key valuation takeaways for investors:
- Premium multiples (P/E, P/B, EV/Sales, EV/EBIT) indicate that the stock is priced for growth; downside risk exists if growth disappoints.
- The absence of a PEG ratio suggests analysts' growth estimates are sparse or inconsistent; investors should scrutinize revenue and EPS growth drivers.
- Dividend metrics show limited income appeal; total-return considerations should focus on capital appreciation tied to execution.
- Enterprise value roughly equals market cap, implying a neutral net debt position - confirm balance sheet items for exact leverage profile.
Additional context on strategic direction and corporate priorities is available here: Mission Statement, Vision, & Core Values (2026) of Novoray Corporation.
Novoray Corporation (688300.SS) - Risk Factors
Novoray Corporation (688300.SS) faces a constellation of operational, market, regulatory and macroeconomic risks that can materially affect near-term cash flow, margins and long-term valuation. Below are the principal risk vectors, quantified where possible and contextualized for investor assessment.
- Fluctuations in raw material and energy costs
Key inputs (e.g., petrochemical feedstocks, specialty intermediates, natural gas/electricity for process heating) drive variable production cost. Historical and scenario sensitivities can be summarized as:
| Driver | Typical Price Volatility (annual) | Estimated Gross Margin Sensitivity | Notes |
|---|---|---|---|
| Feedstock (petrochemicals) | ±15-30% | ±3-8 percentage points | Higher for high-conversion specialty chemicals |
| Energy (gas/electricity) | ±10-25% | ±1-4 percentage points | Elevated when furnaces/processes are energy-intensive |
| Freight/logistics | ±5-20% | ±0.5-2 percentage points | Significant for exports and bulky intermediates |
- Intensified domestic competition and pricing pressure
Market entry by low-cost domestic producers or capacity additions in China can force price concessions. Typical impact scenarios:
- Small price contraction (-5%): EBITDA margin decline ~1-2 p.p.
- Moderate price war (-10%): EBITDA margin decline ~2-5 p.p., potential volume loss 3-8%
- Severe sustained price pressure (-15%+): strategic margin compression prompting CAPEX deferrals or product mix shift
- Delays in downstream demand, project construction, and new capacity ramp-up
Delays lengthen cash conversion cycles, increase interest expense on construction financing, and defer revenue recognition. Representative metrics for delay impacts:
| Delay Type | Typical Duration | Financial Effect |
|---|---|---|
| Downstream demand slump | 3-12 months | Inventory rise, working capital increase by 5-12% of sales |
| Project/construction delay | 6-24 months | Interest capitalization increases; incremental financing costs 0.5-2% of project capex per annum |
| New capacity ramp-up underperformance | 3-9 months | Lower utilization reduces ROI; unit costs rise 10-20% during ramp |
- Reliance on high-end products and exposure to demand shifts
Concentration in premium specialty segments amplifies volatility: an adverse demand shock in a key specialty (e.g., high-performance resins) can reduce blended ASPs and utilization. Example concentration metrics investors should watch:
- Top 3 product lines contribution to revenue: often 40-60%
- Export share of high-end portfolio: frequently 30-50%
- Customer concentration (top 5 customers): can account for 25-45% of sales in specialty segments
- Regulatory changes in the chemical industry
Shifts in environmental, safety, or trade regulations may require capex for emissions control, reformulation, or certification. Typical fiscal and timing burdens:
| Regulatory Change | One-time CapEx Impact | Recurring Opex Impact | Typical Implementation Lead Time |
|---|---|---|---|
| Emissions control (e.g., SCR, waste treatment) | RMB 50-300 million per plant | +1-3% of sales | 12-36 months |
| Restricted substances / REACH-type compliance | RMB 10-80 million (testing, reformulation) | +0.5-1.5% of sales | 6-24 months |
| Export / trade policy changes | Variable - tariffs or certification costs | Margin compression 0.5-4 p.p. | Immediate to 12 months |
- Currency exchange rate fluctuations
Foreign-denominated sales and imported feedstocks create FX mismatches. Sensitivity examples (assuming partial natural hedging):
| FX Move (CNY vs USD/EUR) | Typical P&L Impact | Balance Sheet / Cash Flow |
|---|---|---|
| CNY depreciation 5% | Exported product revenue in CNY up ~3-5%; imported cost in CNY up 3-6% depending on invoice currency - net impact depends on currency mix | Foreign receivables/repatriation swings; working capital FX translational exposure |
| CNY appreciation 5% | Export competitiveness weakens; reported revenue down in local currency if invoiced in foreign currency | Imported input costs decline; potential margin benefit if inputs are imported |
Key quantitative indicators investors should monitor regularly:
- Gross margin and EBITDA margin trends (quarter-over-quarter and year-over-year)
- Raw material cost as % of revenue and inventory days
- Utilization rates of major plants and new capacity ramp schedules
- Top-customer revenue concentration and product ASP trends
- Net debt / EBITDA and interest coverage ratios (sensitivity to rising rates)
- FX exposure mapping: % of revenues and costs in foreign currencies
For strategic context on the company's stated priorities and long-term orientation see: Mission Statement, Vision, & Core Values (2026) of Novoray Corporation.
Novoray Corporation (688300.SS) - Growth Opportunities
Novoray sits at the intersection of several high-growth semiconductor and communication-materials trends. Key demand drivers align with its product portfolio (high-frequency copper-clad laminates, functional powders, thermal interface materials, alumina powder) and R&D emphasis, supporting medium- to long-term revenue expansion and margin improvement.- High-frequency copper-clad laminates: global demand rising with 5G/5.5G and aerospace/radar; estimated market size ~USD 3.5B (2023) with projected CAGR ~7-9% to 2028.
- 5G / 5.5G infrastructure: densification and higher-frequency bands increase use of low-loss, high-Tg laminates-driving per-board material ASP lifts of 5-12% versus legacy materials.
- Advanced packaging (Chiplet, HBM): packaging materials market expanding rapidly-addressable market for Novoray's specialized substrates and powders estimated to grow at ~10-15% CAGR over the next 5 years.
- Functional powder R&D: in-house development of high-purity dielectric and magnetic powders supports new product launches and higher-margin specialty sales; target R&D allocation typically 4-8% of revenue in industry peers.
- Thermal interface materials (TIM): battery energy density improvements and EV adoption expand TIM demand-global TIM market ~USD 1.8B (2023) with CAGR ~8-10% to 2028.
- Alumina powder localization: reducing import reliance can cut COGS volatility and import-related tariff/exchange impacts-domestic alumina capacity increases can reduce procurement costs by an estimated 8-15% versus imported grades.
| Opportunity | Market Size / Baseline (2023) | Projected CAGR | Potential Impact on Novoray |
|---|---|---|---|
| High-frequency laminates | USD 3.5B | 7-9% ('23-'28) | Higher ASPs; +3-6% annual revenue contribution from premium products |
| 5G / 5.5G upgrades | Macro capex cycle (network densification) | Platform-driven uplifts; regional variance | Increased share of high-margin RF material sales |
| Advanced packaging substrates | USD ~20B (packaging ecosystem) | 10-15% (near-term) | New product lines; premium pricing for chiplet/HBM-ready materials |
| Functional powders (R&D) | Specialty powders niche-growing demand | 8-12% | Differentiation; licensing/ODM opportunities |
| Thermal interface materials | USD 1.8B | 8-10% | Addressable EV and battery-pack market; volume growth |
| Localized alumina powder | Domestic substitution potential-significant for China market | - | Lower supply risk; margin stabilization |
- Product mix shift toward high-frequency and advanced-packaging materials raises blended gross margin (peer shifts show +200-600 bps over 3-5 years).
- R&D-driven proprietary powder chemistries enable premium pricing and faster time-to-market for next-gen substrates.
- Verticalizing supply (alumina powder) reduces procurement cost volatility and shortens lead times in tight supply cycles.
- Expanding TIM portfolio enables cross-selling into existing customer relationships (PCB + thermal solutions), increasing wallet share per OEM.
- Revenue mix: % of sales from high-frequency / advanced packaging products (target >25% over 3 years for material margin uplift).
- R&D spend as % of revenue (industry-leading peers: ~4-8%); product launches and patent filings per year.
- Gross margin trend and ASPs for premium laminates vs. standard laminates (watch for +200-600 bps improvement if mix shift succeeds).
- Domestic alumina production capacity ramp (tons/month) and realized cost delta versus imported material.
Novoray Corporation (688300.SS) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.